SEC Tracker
Get the app

Hims & Hers Health HIMS

Hims & Hers Health FY 2024: revenue $1.5B, up 69%; diluted EPS $0.53

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.12
Material contract
Exhibit 10.13
Material contract
Exhibit 10.14
Material contract

Key figures from this report

These are the numbers Hims & Hers Health reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.5B+69% from $872.0M in FY 202310-K income statement, on EDGAR
  2. Net income$126.0MAgainst −$23.5M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$0.53Against −$0.11 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$220.6M+128% from $96.7M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations$251.1M+242% from $73.5M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Hims & Hers Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8011 and related industry codes: the same peer list as the financial tables.

  1. Teladoc Health TDOC public float $1.5B, Jun 30, 2025
  2. LifeMD LFMD public float $512M, Jun 30, 2025
  3. Starling Oncology TOI public float $137M, Jun 30, 2025
  4. Airsculpt Technologies AIRS public float $80M, Jun 30, 2025
  5. SBC Medical Group Holdings SBC public float $48M, Jun 30, 2025